

Sarah K Tasian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7816248/publications.pdf>

Version: 2024-02-01

121
papers

5,719
citations

136950

32
h-index

82547

72
g-index

129
all docs

129
docs citations

129
times ranked

6920
citing authors

#	ARTICLE	IF	CITATIONS
1	Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice. <i>Leukemia</i> , 2022, 36, 42-57.	7.2	16
2	Molecular and phenotypic diversity of CBL/I^{-} -mutated juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2022, 107, 178-186.	3.5	25
3	Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies. <i>Blood Cancer Discovery</i> , 2022, 3, 103-115.	5.0	31
4	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer. <i>European Journal of Cancer</i> , 2022, 160, 112-133.	2.8	24
5	CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2022, 40, 252-261.	1.6	18
6	Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TAEL2014-001). <i>Haematologica</i> , 2022, 107, 2295-2303.	3.5	8
7	Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. <i>Blood</i> , 2022, 140, 619-629.	1.4	45
8	Minimal residual disease comparison between Ig/TCR PCR versus NGS assays in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: A report from the COG AALL1631 study. <i>Journal of Clinical Oncology</i> , 2022, 40, 10023-10023.	1.6	1
9	Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia. <i>Haematologica</i> , 2021, 106, 1067-1078.	3.5	15
10	Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28718.	1.5	30
11	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Cancer Discovery</i> , 2021, 11, 1424-1439.	9.4	16
12	Diagnostic Challenges in Pediatric Hemophagocytic Lymphohistiocytosis. <i>Journal of Clinical Immunology</i> , 2021, 41, 1213-1218.	3.8	10
13	Direct long-read RNA sequencing identifies a subset of questionable exons likely arising from reverse transcription artifacts. <i>Genome Biology</i> , 2021, 22, 190.	8.8	20
14	Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2021, 138, 1465-1480.	1.4	34
15	Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 5109-5122.	7.0	8
16	Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR/i^{-} -rearranged Philadelphia chromosome-like acute lymphoblastic leukemia. <i>Haematologica</i> , 2021, 106, 2763-2767.	3.5	12
17	Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. <i>Journal of Clinical Investigation</i> , 2021, 9, e003149.		28
18	Are we ABL to do better for children with BCR-ABL1-like acute lymphocytic leukaemia?. <i>Lancet Haematology</i> , 2021, 8, e6-e8.	4.6	0

#	ARTICLE	IF	CITATIONS
19	Phat Mass and Ph-like ALL: A Link Between Obesity and CRLF2 Rearrangements?. , 2021, 18, .		0
20	Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?. Best Practice and Research in Clinical Haematology, 2021, 34, 101331.	1.7	6
21	Ph-Like ALL: Diagnosis and Management. Hematologic Malignancies, 2021, , 235-247.	0.2	0
22	Transcriptomic Features of Immune Exhaustion and Senescence Predict Outcomes and Define Checkpoint Blockade-Unresponsive Microenvironments in Acute Myeloid Leukemia. Blood, 2021, 138, 223-223.	1.4	1
23	Transient atypical monocytosis after $\hat{1}\pm/\hat{1}^2$ Tâ€œcellâ€œdepleted haploidentical hematopoietic stem cell transplantation. Pediatric Blood and Cancer, 2020, 67, e28139.	1.5	1
24	The future of cellular immunotherapy for childhood leukemia. Current Opinion in Pediatrics, 2020, 32, 13-25.	2.0	13
25	Targeted therapy or transplantation for paediatric ABL-class Ph-like acute lymphocytic leukaemia?. Lancet Haematology,the, 2020, 7, e858-e859.	4.6	3
26	Diverse noncoding mutations contribute to deregulation of cis-regulatory landscape in pediatric cancers. Science Advances, 2020, 6, eaba3064.	10.3	14
27	Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Science Translational Medicine, 2020, 12, .	12.4	117
28	Clinical diagnostics and treatment strategies for Philadelphia chromosomeâ€œlike acute lymphoblastic leukemia. Blood Advances, 2020, 4, 218-228.	5.2	69
29	Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL. Journal of Clinical Investigation, 2020, 130, 3637-3653.	8.2	30
30	Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group. Blood, 2020, 136, 45-46.	1.4	6
31	DYRK1A Is Required to Alleviate Replication Stress in KMT2A-Rearranged Acute Lymphoblastic Leukemia. Blood, 2020, 136, 39-40.	1.4	2
32	Abstract B63: Immune gene expression profiling of acute myeloid leukemia identifies predictors of survival and actionable targets for treatment. , 2020, , .		0
33	Clinical significance of serial tumor next generation sequencing (NGS) in 155 pediatric cancer patients.. Journal of Clinical Oncology, 2020, 38, e13666-e13666.	1.6	1
34	Temsirolimus combined with etoposide and cyclophosphamide for relapsed/refractory acute lymphoblastic leukemia: Therapeutic advances in Childhood Leukemia Consortium (TACL 2014-001) trial.. Journal of Clinical Oncology, 2020, 38, 10512-10512.	1.6	1
35	Abstract 3234: Multi-antigen targeting of CD19, CD22 and TSLPR to prevent Ph-like ALL resistance. , 2020, , .		1
36	Abstract 3893: Novel synergistic targets for combination therapy in Philadelphia chromosome-like acute lymphoblastic leukemia. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
37	Abstract 5120: Surveying the AML surfaceome for novel immunotherapeutic targets. , 2020, , .		0
38	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2020, 136, 44-45.	1.4	1
39	An Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 26-27.	1.4	2
40	Reducing Dependence on General Anesthesia for Pediatric Oncology Outpatients Undergoing Repeated Lumbar Punctures. <i>Blood</i> , 2020, 136, 9-10.	1.4	0
41	Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells. <i>Leukemia</i> , 2019, 33, 181-190.	7.2	43
42	Development and Clinical Validation of a Large Fusion Gene Panel for Pediatric Cancers. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 873-883.	2.8	41
43	Clinical utility of custom-designed NGS panel testing in pediatric tumors. <i>Genome Medicine</i> , 2019, 11, 32.	8.2	79
44	Targeting Leukemia Stem Cells and the Immunological Bone Marrow Microenvironment. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 153-172.	0.1	2
45	Opportunities for immunotherapy in childhood acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 3750-3758.	5.2	25
46	A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study. <i>Blood Advances</i> , 2019, 3, 1330-1346.	5.2	36
47	Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. <i>Oncogene</i> , 2019, 38, 2241-2262.	5.9	29
48	Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123 α -CD3 Bispecific Dart α Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 460-460.	1.4	2
49	Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. <i>Blood</i> , 2019, 134, 459-459.	1.4	6
50	PI3K γ Inhibition Enhances Sensitivity of Primary High-Risk Childhood B-Cell Acute Lymphoblastic Leukemia Cells to Glucocorticoid Chemotherapy. <i>Blood</i> , 2019, 134, 2572-2572.	1.4	0
51	DYRK1A Is Regulated By Oncogenic KMT2A and Required for Survival of KMT2A-Rearranged Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 2742-2742.	1.4	0
52	Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL. <i>Blood</i> , 2019, 134, 747-747.	1.4	1
53	Glucocorticoids Regulate the Splicing Factor MBNL1, a Potential Control Point for B-Cell Specification. <i>Blood</i> , 2019, 134, 2478-2478.	1.4	0
54	Opportunities for immunotherapy in childhood acute myeloid leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 218-225.	2.5	1

#	ARTICLE	IF	CITATIONS
55	Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. <i>Oncotarget</i> , 2018, 9, 8027-8041.	1.8	42
56	Aberrant splicing in B-cell acute lymphoblastic leukemia. <i>Nucleic Acids Research</i> , 2018, 46, 11357-11369.	14.5	39
57	Approach to Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S6-S8.	0.4	0
58	Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with <i>GOLGA5-JAK2</i> fusion and induction failure. <i>Haematologica</i> , 2018, 103, e427-e431.	3.5	56
59	Targeting Leukemia Stem Cells in the Bone Marrow Niche. <i>Biomedicines</i> , 2018, 6, 22.	3.2	14
60	Generation of a human Juvenile myelomonocytic leukemia iPSC line, CHOPi001-A, with a mutation in CBL. <i>Stem Cell Research</i> , 2018, 31, 157-160.	0.7	11
61	Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 135-148.	2.5	53
62	Abstract 1630: FLT3 chimeric antigen receptor T cell therapy induces B to T cell lineage switch in infant acute lymphoblastic leukemia. , 2018, , .		2
63	A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase. <i>Blood</i> , 2018, 132, 555-555.	1.4	42
64	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Blood</i> , 2018, 132, 261-261.	1.4	3
65	Matched targeted therapy for pediatric patients with relapsed, refractory or high-risk leukemias: A report from the LEAP consortium.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10518-10518.	1.6	1
66	Capturing the complexity of the immune microenvironment of acute myeloid leukemia with 3D biology technology.. <i>Journal of Clinical Oncology</i> , 2018, 36, 50-50.	1.6	8
67	mTOR inhibition enhances efficacy of dasatinib in <i>ABL</i> -rearranged Ph-like B-ALL. <i>Oncotarget</i> , 2018, 9, 6562-6571.	1.8	15
68	Abstract 2280: Systematic analysis of causal noncoding mutations in pediatric B-cell acute lymphoblastic leukemia. , 2018, , .		0
69	Abstract B62: Immune gene expression profiling identifies predictors of relapse in childhood acute myeloid leukemia. , 2018, , .		0
70	Immunophenotypic and Genetic Overlap between JMML and CMML. <i>Blood</i> , 2018, 132, 1803-1803.	1.4	0
71	Improved surfaceome coverage with a label-free nonaffinity-purified workflow. <i>Proteomics</i> , 2017, 17, 1600344.	2.2	9
72	Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. <i>Blood</i> , 2017, 129, 2395-2407.	1.4	148

#	ARTICLE	IF	CITATIONS
73	Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, 177-187.	1.4	138
74	Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, 3000-3008.	1.4	48
75	How is the Ph-like signature being incorporated into ALL therapy?. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 222-228.	1.7	16
76	A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114). <i>British Journal of Haematology</i> , 2017, 177, 467-474.	2.5	32
77	Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics. <i>British Journal of Haematology</i> , 2017, 176, 867-882.	2.5	62
78	Philadelphia chromosome-like acute lymphoblastic leukemia. <i>Blood</i> , 2017, 130, 2064-2072.	1.4	198
79	Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia. <i>Frontiers in Pediatrics</i> , 2017, 5, 248.	1.9	25
80	Targeted Therapy and Precision Medicine. , 2017, , 183-200.		1
81	Inhibiting pathways involved in B-cell development enhances sensitivity of B-cell acute lymphoblastic leukemia to glucocorticoids. <i>FASEB Journal</i> , 2017, 31, .	0.5	0
82	Redundant JAK, SRC and PI3 Kinase Signaling Pathways Regulate Cell Survival in Human Ph-like ALL Cell Lines and Primary Cells. <i>Blood</i> , 2017, 130, 717-717.	1.4	3
83	Preclinical Development of FLT3-Redirected Chimeric Antigen Receptor T Cell Immunotherapy for Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1072-1072.	1.4	17
84	mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALL. <i>Blood</i> , 2016, 128, 2763-2763.	1.4	5
85	Evaluating on-Target Toxicity of Hematopoietic-Targeting Cars Demonstrates Target-Nonspecific Suppression of Marrow Progenitors. <i>Blood</i> , 2016, 128, 3357-3357.	1.4	2
86	Adaptive Reactivation of Signaling Pathways As a Novel Mechanism of Resistance to JAK Inhibitors in Ph-like ALL. <i>Blood</i> , 2016, 128, 755-755.	1.4	4
87	Abstract 2438: Genome-wide screen reveals a role for glucocorticoids in B cell development that can be exploited to improve treatment of B cell acute lymphoblastic leukemia. , 2016, , .		0
88	Preclinical Development of a T-Cell ALL CAR Demonstrates That Differences in CAR Membrane Distribution May Impact Efficacy. <i>Blood</i> , 2016, 128, 4019-4019.	1.4	0
89	Childhood acute lymphoblastic leukemia: Integrating genomics into therapy. <i>Cancer</i> , 2015, 121, 3577-3590.	4.1	59
90	A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). <i>Pediatric Blood and Cancer</i> , 2015, 62, 1717-1724.	1.5	103

#	ARTICLE	IF	CITATIONS
91	Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. <i>Blood</i> , 2015, 126, 629-639.	1.4	110
92	CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). <i>Therapeutic Advances in Hematology</i> , 2015, 6, 228-241.	2.5	89
93	Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 1759-1767.	1.4	189
94	Histology of Testicular Biopsies Obtained for Experimental Fertility Preservation Protocol in Boys with Cancer. <i>Journal of Urology</i> , 2015, 194, 1420-1424.	0.4	46
95	Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 2529-2529.	1.4	3
96	Efficient Termination of CD123-Redirected Chimeric Antigen Receptor T Cells for Acute Myeloid Leukemia to Mitigate Toxicity. <i>Blood</i> , 2015, 126, 565-565.	1.4	14
97	Potent Efficacy of Combined PI3K/mTOR and JAK or SRC/ABL Inhibition in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 798-798.	1.4	4
98	Temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukemia (ALL): A Children's Oncology Group study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10029-10029.	1.6	2
99	Mixed Phenotype Acute Leukemia with Low Hypodiploidy in a Pediatric Patient. <i>Journal of Pediatric Oncology</i> , 2015, 3, 24-28.	0.1	4
100	Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. <i>Frontiers in Oncology</i> , 2014, 4, 108.	2.8	92
101	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 1005-1015.	27.0	1,161
102	Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. <i>Blood</i> , 2014, 123, 2343-2354.	1.4	396
103	Dual Targeting of JAK2 Signaling with a Type II JAK2 Inhibitor and of mTOR with a TOR Kinase Inhibitor Induces Apoptosis in CRLF2-Rearranged Ph-like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3706-3706.	1.4	1
104	A phase I study of ruxolitinib in children with relapsed/refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group Phase I Consortium study (ADVL1011).. <i>Journal of Clinical Oncology</i> , 2014, 32, 10019-10019.	1.6	1
105	Molecular Therapeutic Approaches for Pediatric Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2014, 4, 55.	2.8	35
106	Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. <i>Blood</i> , 2013, 121, 4925-4929.	1.4	104
107	Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States. <i>Cancer</i> , 2013, 119, 1916-1923.	4.1	37
108	Anti-CD123 Chimeric Antigen Receptor T Cells (CART-123) Provide A Novel Myeloablative Conditioning Regimen That Eradicates Human Acute Myeloid Leukemia In Preclinical Models. <i>Blood</i> , 2013, 122, 143-143.	1.4	9

#	ARTICLE	IF	CITATIONS
109	In Vivo Efficacy of PI3K Pathway Signaling Inhibition for Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 2672-2672.	1.4	5
110	Development of Anaplastic Wilms Tumor and Subsequent Relapse in a Child With Diaphanospondylodysostosis. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, 548-551.	0.6	9
111	Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study. <i>Blood</i> , 2012, 119, 3512-3522.	1.4	210
112	Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. <i>Blood</i> , 2012, 120, 833-842.	1.4	201
113	Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. <i>Blood</i> , 2012, 120, 3510-3518.	1.4	263
114	Labial Ecthyma Gangrenosum in an Immunocompromised Infant With Leukemia: Heightening Awareness for the Urologist. <i>Urology</i> , 2012, 80, 1366-1368.	1.0	9
115	Mortality and Resource Utilization in Children with De Novo Acute Myeloid Leukemia Treated with Chemotherapy and Gemtuzumab Ozogamicin in the United States. <i>Blood</i> , 2012, 120, 4283-4283.	1.4	0
116	Understanding the Biology of CRLF2-Overexpressing Acute Lymphoblastic Leukemia. <i>Critical Reviews in Oncogenesis</i> , 2011, 16, 13-24.	0.4	39
117	Targeting mTOR and JAK2 in Xenograft Models of CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2011, 118, 249-249.	1.4	1
118	Thymic Stromal Lymphopoietin Stimulation of Pediatric Acute Lymphoblastic Leukemias with CRLF2 Alterations Induces JAK/STAT and PI3K Phosphosignaling. <i>Blood</i> , 2010, 116, 410-410.	1.4	4
119	JAK mutations in high-risk childhood acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 9414-9418.	7.1	516
120	Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1257-1264.	4.2	29
121	Influenza-associated morbidity in children with cancer. <i>Pediatric Blood and Cancer</i> , 2008, 50, 983-987.	1.5	56